SBBPライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs...

Stats
本日の出来高	684 683
平均出来高	316 352
時価総額	0.00
EPS	$-0.0700 ( 2021-08-05 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.111 (5.55%)

Insider Trading

Date	Person	Action	Amount	type
2021-10-05	Cdk Associates, L.l.c.	Sell	8 060 682	Ordinary Shares, $0.01 par value
2021-10-05	Cdk Associates, L.l.c.	Sell	2 220 000	Ordinary Shares Warrant (right to buy)
2021-10-05	Wilhoit Scott L.	Sell	109 510	Ordinary Shares
2021-10-05	Wilhoit Scott L.	Sell	649 000	Stock Option (Right to Buy)
2021-10-05	Kollender Richard S	Sell	234 229	Ordinary Shares

INSIDER POWER
0.00
Last 99 transactions
Buy: 6 188 774 \| Sell: 17 044 650

ボリューム相関

長: 0.22 (neutral)

短: -0.76 (moderate negative)

Signal:(42.06) Neutral

Strongbridge Biopharma 相関

10 最も正の相関
ORRF	0.896
VIEW	0.889
NTCT	0.866
PRCT	0.865
MMAC	0.86
RPRX	0.858
INDB	0.854
TRIT	0.854
HBCP	0.852
SABS	0.852

10 最も負の相関
DFH	-0.93
COUP	-0.912
ICON	-0.91
RDUS	-0.909
CRVL	-0.902
FEYE	-0.9
CVT	-0.899
ARAY	-0.882
ACCD	-0.881
FTDR	-0.88

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Strongbridge Biopharma 相関 - 通貨/商品

0.02
( neutral )

-0.48
( neutral )

0.00
( neutral )

-0.04
( neutral )

0.70
( moderate )

-0.03
( neutral )

Strongbridge Biopharma 財務諸表

Annual	2020
収益:	$30.73M
総利益:	$28.52M (92.80 %)
EPS:	$-0.780

FY	2020
収益:	$30.73M
総利益:	$28.52M (92.80 %)
EPS:	$-0.780

FY	2019
収益:	$21.71M
総利益:	$17.89M (82.40 %)
EPS:	$-0.910

FY	2018
収益:	$18.03M
総利益:	$14.04M (77.89 %)
EPS:	$0.690

Financial Reports:

No articles found.

Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.